Clinical Trials Logo

Stage IIIC Intraocular Melanoma clinical trials

View clinical trials related to Stage IIIC Intraocular Melanoma.

Filter by:
  • None
  • Page 1

NCT ID: NCT02068586 Active, not recruiting - Iris Melanoma Clinical Trials

Sunitinib Malate or Valproic Acid in Preventing Metastasis in Patients With High-Risk Uveal Melanoma

Start date: November 19, 2014
Phase: Phase 2
Study type: Interventional

This randomized phase II trial studies how well sunitinib malate or valproic acid works in preventing high-risk uveal (eye) melanoma from spreading to other parts of the body. Sunitinib malate may stop the transmission of growth signals into tumor cells and prevents these cells from growing. Valproic acid may change the expression of some genes in uveal melanoma and suppress tumor growth.

NCT ID: NCT01533948 Terminated - Recurrent Melanoma Clinical Trials

Axitinib in Treating Patients With Melanoma That is Metastatic or Cannot Be Removed by Surgery

Start date: January 2012
Phase: Phase 2
Study type: Interventional

This phase II trial studies how well axitinib works in treating patients with melanoma that has spread to other places in the body or cannot be removed by surgery. Axitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.

NCT ID: NCT00085189 Completed - Recurrent Melanoma Clinical Trials

Vaccine Therapy in Treating Patients With Stage IIC-IV Melanoma

Start date: May 2004
Phase: Phase 2
Study type: Interventional

This pilot phase II trial studies how well giving vaccine therapy works in treating patients with stage IIC-IV melanoma. Vaccines made from melanoma peptides or antigens may help the body build an effective immune response to kill tumor cells